Agency cost, firm performance and capital structure: The case of listed companies in Vietnam
Tác giả: Le Hoang Yen KhanhTóm tắt:
Agency cost is a prevalent topic among academic society, however, this issue has not been fully examined in Vietnam which is a typical transitional economy with distinguished features from other developing countries. . Although most of these studies are based on qualitative research and confirm the existence of agency cost in Vietnamese companies, they cannot estimate specifically the agency cost. This study is carried out to determine the impact of agency cost (proxies are asset turnover ratio and general and administrative expense ratio) on firm performance (proxy is ROE) of 200 companies listed on Vietnam stock market during the 12 year period from 2008 to 2019, and to figure out the differences in agency cost of privatized corporations (currently dominated by state ownership) and private corporations (only private ownership). Furthermore, the role of capital structure on firm performance is also examined to test whether capital structure can control agency cost in two groups of companies. The research is conducted by using the mixture of quantitative method, and deductive approach. The research findings show that agency cost in privatized firms has more negative influence on firm performance than that of private firms. Furthermore, capital structure and state-ownership impact on firm performance negatively and significantly, while profit growth and country investment have a positive impact on firm performance. Moreover, the differently negative impact of capital structure on firm performance of two groups is also analyzed which can suggests further and intensive research in the future.
- Bào chế và đánh giá chất lượng Siro Nhị Trần
- Tác động của chuyển đổi số đến hiệu quả kinh doanh tại Công ty Cổ phần Dược phẩm Nhóm Bác sĩ–Dược sĩ
- Phát triển công thức bào chế vi cầu nổi chứa piperin
- Đánh giá tình trạng nhiễm trùng huyết tại đơn vị Ghép tế bào gốc- khoa Huyết học - bệnh viện Chợ Rẫy từ năm 2017 đến 6 tháng đầu năm 2024
- Đánh giá đáp ứng sau hóa trị tân hỗ trợ bằng phác đồ Docetaxel, Carboplatin và Trastuzumab ở bệnh nhân ung thư vú có thụ thể HER2 dương tính giai đoạn II, III





